 Heat Biologics Inc NASDAQ: HTBX soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibbs NYSE: BMY Opdivo nivolumab in advanced non-small-cell lung cancer NSCLC. Median progression-free survival PFS of 1.8 months and median overall survival OS of 24.6 months was observed in checkpoint inhibitor naïve patients with advanced NSCLC cohort A, N 47. 